Taiwan's PharmaEssentia got Japanese approval for its drug Ropeg to treat a rare blood disorder, a clear win for the company and a step toward a bigger global market.

• Japan approved Ropeg for essential thrombocythemia, a condition where the body makes too many platelets, raising the risk of clots and bleeding.
• This is the broadest approval yet — Japan cleared it for all patients, including those who have never been treated before, not just those who failed older drugs.
• The disease has seen no new drugs in almost thirty years, so demand is strong.
• Ropeg is already approved in about 50 countries for a related blood disorder, including the US and Europe.
• The company held a US sales meeting this month to be ready to sell the moment American approval lands.

Outlook: The US regulator's decision deadline is at the end of August, and a green light there would open the drug's biggest market yet.